Answer
Deucravacitinib selectively inhibits TYK2 by binding its regulatory domain, blocking receptor-mediated activation and downstream signalling involving IL-23, IL-12 and type I interferons, thereby inhibiting the release of proinflammatory cytokines and chemokines.
Sources for this answer
- SOTYKTU 6 mg film coated tabletsBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 3Document updated
Sources checked